Khavinson Bioregulator Peptides

What Are Bioregulator Peptides?

Starting in the 1970s, Vladimir Khavinson and colleagues at the St. Petersburg (formerly Leningrad) Institute of Bioregulation and Gerontology proposed that very short synthetic peptides -- as short as two amino acids -- could bind chromatin in specific tissue types and activate or normalize gene expression relevant to that tissue's function and aging. This research program produced a family of tissue-targeted peptides, each named for or associated with the tissue it was designed to act on, with published evidence spanning from single-gene-activation studies to long-term animal lifespan trials and a handful of aged human cohort studies.

The Five Compounds by Target Tissue

Epitalon (Ala-Glu-Asp-Gly) is studied for its proposed role in pineal gland function and telomerase activity, matching the amino acid composition of Epithalamin, a pineal-gland extract first described in 1973. Pinealon (Glu-Asp-Arg) targets brain tissue, proposed to cross the blood-brain barrier and modulate gene expression linked to oxidative stress and cognitive aging. Cartalax (Ala-Glu-Asp) targets chondrocytes, proposed to activate transcription of cartilage matrix genes including type II collagen and aggrecan. Thymalin is a calf-thymus-derived polypeptide complex -- a mixture of several distinct thymic peptides, rather than a single defined sequence -- studied for restoring T-cell mediated immunity in aging. Vilon (Lys-Glu) is the shortest compound in the family, a two-amino-acid dipeptide studied for thymic and immune-related gene expression in animal models.

A Shared, Disputed Mechanism

The proposed mechanism common to this entire family -- short peptides directly binding DNA regulatory regions to influence transcription in a tissue-specific way -- remains a disputed hypothesis outside Khavinson's own body of work. Because the compounds share this mechanism and research lineage, they are frequently discussed together in research contexts, even though each targets a different tissue: see how Cartalax compares to Pinealon or how Vilon compares to Thymosin Alpha-1, a structurally unrelated but far more extensively validated immune peptide, or how Epitalon compares to SS-31, a mitochondrial-targeted peptide from an entirely separate research tradition.

Clinical & Preclinical Trial Data

The most-cited human data comes from Khavinson & Morozov (Neuroendocrinology Letters, 2003), which followed a cohort of 266 elderly and senior subjects for 6–8 years after short courses of peptide bioregulators including Thymalin and Epithalamin (Epitalon's pharmaceutical form), reporting a 2.0–2.4-fold decrease in acute respiratory disease incidence and mortality reduction ranging from 1.6× up to roughly 4× versus untreated controls. Pinealon and Cartalax have no human trial data at all -- their evidence is limited to cell-culture and rodent work from Khavinson-affiliated groups. Vilon's core evidence is a single, decades-old animal lifespan study (Khavinson & Anisimov), in which chronic administration extended lifespan by 20–40% in female CBA mice. None of this research has been independently replicated in a large Western multi-center trial, and the FDA has not evaluated any compound in this family. See the individual research profiles for Epitalon, Pinealon, Cartalax, Thymalin, and Vilon for the full evidence picture on each compound.

Availability

Epitalon and Pinealon are part of KYIN Peptides' standard catalogue, including together in our Longevity Bundle. Cartalax, Thymalin, and Vilon are not currently stocked but are available to order — contact us directly and we'll source them for you.